3-D Bioprinting: Islet Micro-tissues to Redistribute Manufacture for Treatment of Type 1 Diabetes
Type 1 diabetes is an autoimmune disorder where the body’s native insulin producing β-cells in the pancreas are destroyed and are consequently unable to maintain normal blood glucose levels. There are currently 3.2 Million people diagnosed with diabetes in the UK, 10% of the yearly budget of the NHS goes to treating diabetes and its complications. The project seeks to improve the patient outcomes of type 1 diabetes treatment, whilst making it more efficient and reducing overall costs. The aim is to develop functional islet micro-tissue(s) by 3-D printing viable islet cells and to assess the potential this would have in terms of re-defining the supply chain for regenerative approaches to the treatment of diabetes.